诱导多能干细胞在原发性免疫缺陷症的研究和治疗中的作用。
The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies.
机构信息
Division of Hematology/Oncology, Children's Hospital Boston, Boston, USA.
出版信息
Curr Opin Immunol. 2012 Oct;24(5):617-24. doi: 10.1016/j.coi.2012.07.001. Epub 2012 Jul 25.
Abstract
The advent of reprogramming technology has greatly advanced the field of stem cell biology and nurtured our hope to create patient specific renewable stem cell sources. While the number of reports of disease specific induced pluripotent stem cells is continuously rising, the field becomes increasingly more aware that induced pluripotent stem cells are not as similar to embryonic stem cells as initially assumed. Our state of the art understanding of human induced pluripotent stem cells, their capacity, their limitations and their promise as it pertains to the study and treatment of primary immunodeficiencies, is the content of this review.
摘要
重编程技术的出现极大地推动了干细胞生物学领域的发展，并激发了我们创造患者特异性可再生干细胞来源的希望。虽然与疾病相关的诱导多能干细胞的报道数量不断增加，但该领域越来越意识到诱导多能干细胞并不像最初假设的那样与胚胎干细胞相似。本文综述了我们对人类诱导多能干细胞的最新认识，包括它们的能力、局限性及其在原发性免疫缺陷研究和治疗中的应用。
相似文献
1
The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies.
Curr Opin Immunol. 2012 Oct;24(5):617-24. doi: 10.1016/j.coi.2012.07.001. Epub 2012 Jul 25.
2
[Breakthrough in research on pluripotent stem cells and their application in medicine].
Laeknabladid. 2015 Dec;101(12):581-6. doi: 10.17992/lbl.2015.12.56.
3
Induced pluripotent stem cells and primary immunodeficiencies: a new frontier reached, a new world beyond?
J Allergy Clin Immunol. 2011 Jun;127(6):1408-9. doi: 10.1016/j.jaci.2011.02.038. Epub 2011 Mar 24.
4
Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy.
Circ J. 2017 Jun 23;81(7):929-935. doi: 10.1253/circj.CJ-17-0400. Epub 2017 Jun 10.
5
The 'sweet' spot of cellular pluripotency: protein glycosylation in human pluripotent stem cells and its applications in regenerative medicine.
Expert Opin Biol Ther. 2015 May;15(5):679-87. doi: 10.1517/14712598.2015.1021329. Epub 2015 Mar 3.
6
Defining Human Pluripotency.
Cell Stem Cell. 2019 Jul 3;25(1):9-22. doi: 10.1016/j.stem.2019.06.010.
7
Reprogrammed cells for disease modeling and regenerative medicine.
Annu Rev Med. 2013;64:277-90. doi: 10.1146/annurev-med-050311-163324.
8
Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
Pharmacol Ther. 2010 May;126(2):109-18. doi: 10.1016/j.pharmthera.2010.01.010. Epub 2010 Feb 13.
9
Human Pluripotent Stem Cell Mechanobiology: Manipulating the Biophysical Microenvironment for Regenerative Medicine and Tissue Engineering Applications.
Stem Cells. 2015 Nov;33(11):3187-96. doi: 10.1002/stem.2105. Epub 2015 Jul 29.
10
Clinical potentials of human pluripotent stem cells.
Cell Biol Toxicol. 2017 Aug;33(4):351-360. doi: 10.1007/s10565-017-9384-y. Epub 2017 Feb 8.
引用本文的文献
1
In Vitro Model Systems to Study Human T Cell Development.
Methods Mol Biol. 2023;2580:335-354. doi: 10.1007/978-1-0716-2740-2_21.
2
Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies.
Blood. 2016 Aug 11;128(6):783-93. doi: 10.1182/blood-2015-10-676304. Epub 2016 Jun 14.
3
A novel common gamma chain mutation in a Chinese family with X-linked severe combined immunodeficiency (X-SCID; T(-)NK(-)B(+)).
Immunogenetics. 2015 Nov;67(11-12):629-39. doi: 10.1007/s00251-015-0871-0. Epub 2015 Sep 26.
4
Deciphering Human Cell-Autonomous Anti-HSV-1 Immunity in the Central Nervous System.
Front Immunol. 2015 May 8;6:208. doi: 10.3389/fimmu.2015.00208. eCollection 2015.
5
Granule protein processing and regulated secretion in neutrophils.
Front Immunol. 2014 Sep 19;5:448. doi: 10.3389/fimmu.2014.00448. eCollection 2014.
6
Bottlenecks in deriving definitive hematopoietic stem cells from human pluripotent stem cells: a CIRM mini-symposium and workshop report.
Stem Cells Transl Med. 2014 Jul;3(7):775-81. doi: 10.5966/sctm.2014-0104.
本文引用的文献
1
Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency.
Front Immunol. 2011 Nov 8;2:54. doi: 10.3389/fimmu.2011.00054. eCollection 2011.
2
Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles.
Curr Opin Hematol. 2012 Jul;19(4):256-60. doi: 10.1097/MOH.0b013e328353c78f.
3
Retrovirus and lentivirus vector design and methods of cell conditioning.
Methods Enzymol. 2012;507:29-57. doi: 10.1016/B978-0-12-386509-0.00003-X.
4
Hematopoiesis: a human perspective.
Cell Stem Cell. 2012 Feb 3;10(2):120-36. doi: 10.1016/j.stem.2012.01.006.
5
The promise of induced pluripotent stem cells in research and therapy.
Nature. 2012 Jan 18;481(7381):295-305. doi: 10.1038/nature10761.
6
Homologous recombination-based gene therapy for the primary immunodeficiencies.
Ann N Y Acad Sci. 2011 Dec;1246:131-40. doi: 10.1111/j.1749-6632.2011.06314.x.
7
A transcription activator-like effector toolbox for genome engineering.
Nat Protoc. 2012 Jan 5;7(1):171-92. doi: 10.1038/nprot.2011.431.
8
Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells.
Nat Biotechnol. 2011 Nov 27;29(12):1117-9. doi: 10.1038/nbt.2052.
9
In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.
Stem Cells. 2011 Nov;29(11):1717-26. doi: 10.1002/stem.718.
10
Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.
Blood. 2011 Oct 27;118(17):4599-608. doi: 10.1182/blood-2011-02-335554. Epub 2011 Aug 31.
Zotero 插件